Teva Begins Direct Trading on NYSE Marking Strategic Transformation Milestone
News related to:Teva Pharmaceutical Industries Ltd · 1 min read
Teva Pharmaceutical Industries Ltd. began trading its ordinary shares directly on the New York Stock Exchange (NYSE) on September 14, 2026, marking a significant milestone in the company’s strategic transformation. This move follows the completion of the firm’s planned transition from its American Depositary Shares (ADS) program.
Richard Francis, President and CEO of Teva, expressed that the direct listing on the NYSE is a crucial step in the company’s Pivot to Growth strategy.
According to Teva, the direct listing is part of a broader strategy to transform the company into a leading innovative biopharmaceutical firm. The firm has been focusing on expanding its innovative and biosimilar medicines pipeline and profitably commercializing its innovative medicines and biosimilar portfolio. Additionally, Teva is committed to sustaining and focusing its portfolio of generic medicines while executing on its organizational transformation to achieve expected cost savings.
Teva’s innovative pipeline includes three flagship brands, AUSTEDO®, AJOVY®, and UZEDY®, which have collectively grown by more than 40% year-over-year. The company expects these brands to generate approximately $3.7 billion in revenues in 2026. Furthermore, Teva has received investment-grade ratings across all three major agencies, underscoring the company’s financial strength, disciplined execution, and ongoing debt reduction.
The company is also well-positioned for future growth, with multiple near-term pipeline and commercial catalysts ahead. Teva’s pipeline has the potential to generate more than $10 billion in peak revenues, positioning the company to expand margins, grow earnings, and create significant long-term shareholder value.
In summary, Teva’s direct listing on the NYSE is a significant step in its strategic transformation, aimed at broadening investor access and enhancing its financial and operational performance. The company remains focused on delivering for patients, driving sustainable growth, and accelerating its journey to become a leading innovative biopharmaceutical company.